PMID- 36289661
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221030
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 10
IP  - 10
DP  - 2022 Sep 26
TI  - Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and 
      Intramacrophagic Mycobacteria.
LID - 10.3390/biomedicines10102398 [doi]
LID - 2398
AB  - As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the 
      world population is infected with the well-known latent tuberculosis (LTBI). 
      About 5-10% of LTBI patients will progress to active disease in the first years 
      after primary infection and, despite using the recommended treatment, 20% can 
      still reactivate the infection. A new LTBI treatment could minimize adverse 
      effects and antibiotic resistance that can occur when the same drug is used to 
      treat the latent and active disease. New hydrazones were evaluated, and they 
      showed great inhibitory activity against intramacrophagic and non-replicating M. 
      tb, commonly found at this stage of infection, in addition to bactericidal and 
      narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones 
      showed great safety at different exposure times. In vitro, these compounds 
      performed better than isoniazid and could be considered new candidates for LTBI 
      treatment, which may promote greater engagement in its prescription and 
      adherence.
FAU - Campos, Debora Leite
AU  - Campos DL
AD  - Tuberculosis Research Laboratory, School of Pharmaceutical Sciences, Sao Paulo 
      State University-UNESP, Araraquara 14800-903, Brazil.
FAU - Demarqui, Fernanda Manaia
AU  - Demarqui FM
AD  - Tuberculosis Research Laboratory, School of Pharmaceutical Sciences, Sao Paulo 
      State University-UNESP, Araraquara 14800-903, Brazil.
FAU - Solcia, Mariana Cristina
AU  - Solcia MC
AD  - Tuberculosis Research Laboratory, School of Pharmaceutical Sciences, Sao Paulo 
      State University-UNESP, Araraquara 14800-903, Brazil.
FAU - de Souza, Paula Carolina
AU  - de Souza PC
AUID- ORCID: 0000-0001-8496-0436
AD  - Tuberculosis Research Laboratory, School of Pharmaceutical Sciences, Sao Paulo 
      State University-UNESP, Araraquara 14800-903, Brazil.
FAU - da Silva Maia, Pedro Ivo
AU  - da Silva Maia PI
AUID- ORCID: 0000-0003-4699-9481
AD  - Institute of Exact, Natural Sciences and Education, Triangulo Mineiro Federal 
      University-UFTM, Uberaba 38064-200, Brazil.
FAU - Deflon, Victor Marcelo
AU  - Deflon VM
AD  - Institute of Exact, Natural Sciences and Education, Triangulo Mineiro Federal 
      University-UFTM, Uberaba 38064-200, Brazil.
FAU - Pavan, Fernando Rogerio
AU  - Pavan FR
AUID- ORCID: 0000-0002-6969-3963
AD  - Tuberculosis Research Laboratory, School of Pharmaceutical Sciences, Sao Paulo 
      State University-UNESP, Araraquara 14800-903, Brazil.
LA  - eng
GR  - 2020/13497-4/Sao Paulo Research Foundation/
GR  - 2018/21778-3/Sao Paulo Research Foundation/
GR  - 303603/2018-6/National Council for Scientific and Technological Development/
GR  - 001/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/
PT  - Journal Article
DEP - 20220926
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC9598318
OTO - NOTNLM
OT  - Mycobacterium tuberculosis
OT  - latent tuberculosis
OT  - treatment
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/28 06:00
MHDA- 2022/10/28 06:01
PMCR- 2022/09/26
CRDT- 2022/10/27 01:01
PHST- 2022/07/26 00:00 [received]
PHST- 2022/08/23 00:00 [revised]
PHST- 2022/09/11 00:00 [accepted]
PHST- 2022/10/27 01:01 [entrez]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/28 06:01 [medline]
PHST- 2022/09/26 00:00 [pmc-release]
AID - biomedicines10102398 [pii]
AID - biomedicines-10-02398 [pii]
AID - 10.3390/biomedicines10102398 [doi]
PST - epublish
SO  - Biomedicines. 2022 Sep 26;10(10):2398. doi: 10.3390/biomedicines10102398.